Navigation Links
Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
Date:9/23/2011

after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
2. Amgen to Present at the Morgan Stanley Global Healthcare Conference
3. Amgen to Present at the Baird Healthcare Conference
4. Amgen to Present at the Stifel Nicolaus Healthcare Conference
5. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
6. Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
7. Amgen Announces Webcast of 2011 Second Quarter Financial Results
8. Amgen Resolves G-CSF Patent Litigation With Teva
9. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
10. Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
11. Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., a ... has launched the FreeRunner™ knee brace with new ... from patella mal-tracking return to active lifestyles.  FreeRunner,s ... other braces, providing support when patients need it ... they don,t. Patellofemoral issues are the ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:7/10/2014)... 10, 2014 Register to download the ... streamed the live webinar ‘Capitalizing on the Shifting Sands ... group of several M&A experts in the energy sector ... energy transaction marketplace. These experts shared their insights into ... market in this sector has been revitalized. This roundtable ...
(Date:7/10/2014)... 2014 Best Drug Rehabilitation ... having family close by during a stay in ... or not the process is successful, has launched ... at http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success ... from several Best Drug Rehabilitation graduates who wanted ...
(Date:7/10/2014)... Colo. (July 8, 2014) A new study from ... modest improvements, poor oral health remains a major problem ... , "The oral health among Native Americans is abysmal ... rest of the country," said Terrence Batliner, DDS, MBA, ... Research at the School of Public Health. "The number ...
(Date:7/10/2014)... -- Adults with dyslexia are more likely to report ... than people who don,t have the learning disorder, according ... up to 10 percent of people, causes problems with ... adults with this condition said they suffered physical abuse ... without dyslexia. "Even after accounting for age, race, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... regularly between outspoken celebrities or loudmouth pundits -- too much ... study suggests. High amounts of Twitter use can lead ... in a long-term relationship, according to findings from an online ... can lead to cheating and breakups, the researchers concluded, although ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... the Black Death as the world's worst pandemic if the ... get life prolonging drugs. The illness has killed 25 million ... infected each day with HIV, which destroys the immune system. ... will die, pushing the death toll beyond the 40 million ...
... suffer from asphyxia, which can lead to brain injury, multiple ... cent of babies who suffer from a moderate lack of ... no effective treatments to reduce the risk of asphyxia at ... a baby's temperature may have beneficial effects. ,UK researchers ...
... in the alpha gene are the cause of premature menopause ... about 2% of the total population. ,The University of ... of a genetic test, which would allow women// with a ... at risk. They analysed DNA from women who had experienced ...
... undergoing coronary artery bypass surgery is rising, even though ... artery bypass surgery uses a blood vessel from another ... or clogged arteries in the heart. A buildup of ... known as atherosclerosis. ,In the new study, ...
... FDA issued a statement about the potential for depression and ... reports say that the 15-year-old pilot who crashed his plane ... investigators don't know whether or not the teen, Charles J. ... death. Blood tests should reveal if the drug was in ...
... from the Institute of Health Sciences in Oxford found that ... likely to have a stillbirth, or to develop pre-eclampsia.// Taking ... the researchers. ,The researchers reviewed more than 23 ... benefits of anti-platelet drugs, of which low-dose aspirin is the ...
Cached Medicine News:
ThermalSeal RT (5mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates. Will not wrinkle in the freezer....
DMSO-resistant microplate sealing film...
Sealing tape featuring 3M adhesive technology. Opaque and strong. Prevents photo-degradation....
Aluminum Seal, Reflective, Bulk...
Medicine Products: